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Abstract
Background: The purpose of the study was to evaluate the impact of multiple prognostic factors on the acute skin
reaction in adjuvant breast cancer radiotherapy, in particular the impact of hypofractionation (HF) compared to
conventional fractionation (CF) and tangential beam (TB) IMRT compared to three-dimensional conformal
radiotherapy (3DCRT).
Methods: Two-hundred and sixty-six breast cancer patients with postoperative radiotherapy after breast conserving
surgery or mastectomy were retrospectively evaluated. Patients were treated with HF (15 fractions of 2.67 Gy;
n = 121) or CF (28 fractions of 1.8 Gy or 25 fractions of 2.0 Gy; n = 145) and TB-IMRT (n = 151) or 3DCRT (n = 115).
The acute skin reactions were prospectively assessed using the CTCAE v4 grading scale. Ordinal regression analysis
was used to assess the impact of possible prognostic factors on the maximal acute skin reaction.
Results: Grade 2 skin reactions were observed in 19 % of the patients treated with CF compared to 2 % treated
with HF. On univariate analysis, the fractionation regimen, the PTV (breast versus chest wall), the volume of the PTV
and the body mass index were significant prognostic factors for the maximum acute skin reaction. On multivariate
analysis, the fractionation regimen (p < 0.00001) and the volume of the PTV (p = 0.0002) remained as independent
significant factors.
Conclusions: Our data suggest that HF is associated with a significantly reduced maximal acute skin reaction
compared to CF.
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Background
Breast cancer is the most common cancer in women
worldwide, and after lung cancer the second most com-
mon cancer overall. In 2012, nearly 1.7 million new
breast cancer cases were diagnosed representing about
12 % of all new cancer cases and 25 % of all cancers in
women [1].
Adjuvant radiotherapy is an important part of breast
cancer management. Conventional fractionation regi-
mens (CF) consisting of 25 daily fractions of 2.0 Gy or
28 daily fractions of 1.8 Gy have generally been consid-
ered the “standard” adjuvant radiotherapy prescription.
Several large, well-conducted randomized trials have
established that hypofractionated regimens (HF) such as
15 daily fractions of 2.67 Gy can be equally effective in
terms of long-term disease control and late radiation ef-
fects compared to the excellent outcomes of more pro-
tracted conventional fractionation schedules [2–5]. The
HF evaluated in the recent trials were characterized by
an increase of the daily fraction dose and a decrease of
the total dose at the same time. The reduced number of
daily fractions compared to CF results in a benefit to pa-
tients and health services in terms of convenience and
cost. Most human cancer types respond to the total dose
rather than to the size of the daily fractions [6]. In con-
trast, the late reacting normal tissues respond to the
daily fraction size (higher fraction doses increase the risk
of late toxicity) and the total dose [7]. The late adverse
effects are dose limiting. CF typically use “small” daily
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fraction doses of 2.0 Gy or 1.8 Gy to deliver the highest
possible tolerated total dose, thereby ensuring the high-
est rate of tumor control. The finding of comparable late
toxicity and long-term tumor control with HF (using
“higher” fraction doses) compared to CF (using “small”
fraction doses) of the recent studies suggests that breast
cancer is an exception in showing comparable sensitivity
to fraction size as the normal tissues of the breast and
ribcage [8].
Like most human cancer types, early reacting normal
tissues respond to the total dose rather than to the size
of the daily fractions. Due to the lower total dose used
with HF compared to CF it can be expected that the
acute radiation reactions are lower in patients treated
with HF. However, the reports of randomized trials to
date have provided little information comparing acute
toxic effects with HF as compared with CF [2, 3, 9–11].
Several randomized [12, 13] and retrospective studies
[14–16] have suggested that the radiation technique may
influence the acute toxic effects in adjuvant breast
cancer radiotherapy. Patients treated with intensity mod-
ulated radiotherapy (IMRT) showed less acute skin reac-
tions compared to patients treated with standard
tangential beam technique using wedge compensation.
This observation has been explained with the improve-
ment in the dose distribution homogeneity using breast
IMRT compared to standard radiotherapy using wedges
[12]. Due to the mathematical form of the linear-
quadratic dose effect relationship, hot spots are penal-
ized more severely in a hypofractionated treatment, so-
called ‘triple trouble’ [8, 17]. It can therefore be expected
that IMRT is in particular beneficial in patients treated
with HF. Commonly used beam configurations for breast
IMRT are tangential beams (TB-IMRT) or multiple
beams from four to seven directions.
Although not a dose limiting factor in breast cancer
radiotherapy, acute skin reactions are of clinical import-
ance. Acute skin toxicity affects multiple dimensions of
quality of life. They cause physical discomfort, body image
disturbance, emotional distress, and impair both day-to-
day functioning and satisfaction with radiation treatment
[12, 18]. Goal of this study was to evaluate the impact of
multiple prognostic factors on the acute skin reaction in
breast cancer radiotherapy, in particular the impact of HF
compared to CF and TB-IMRT compared to 3DCRT.
Patients and methods
Patient population
Two-hundred and sixty-six breast cancer patients with
postoperative radiotherapy after breast conserving sur-
gery or mastectomy between March 2014 and April
2016 were evaluated in this study. The acute skin radi-
ation reaction of all patients was prospectively assessed
once weekly during and 6 weeks after radiotherapy by
two observers using the “dermatitis radiation” grade of the
Common Terminology Criteria for Adverse Events
(CTCAE v4.03) (Table 1). The dermatitis radiation grade
was documented immediately after assessment in the
Local Area Network Therapy Information System “Lantis”
(Siemens Healthcare, Germany), and a table with all
weekly assessments was included in the “End of Treat-
ment Report” of all patients. The two observers were not
involved in the statistical analysis of the study. Patient and
treatment related data were transferred into a database,
anonymized and retrospectively analyzed using specific
statistical software. The study was approved by the local
institutional ethical committee and conducted in accord-
ance with the Helsinki Declaration in its current version.
Patients with the histologically proven diagnosis of breast
cancer or breast cancer in situ receiving postoperative
radiotherapy of the whole breast after breast conserving
surgery or of the chest wall after mastectomy were eligible
for the study. Patients with bilateral breast cancer or a his-
tory of previous radiotherapy of the chest were excluded
from the analysis. Patients were offered a hypofractionated
or conventionally fractionated radiotherapy using inverse
planned tangential beam intensity modulated radiotherapy
(TB-IMRT) or three-dimensional planned conformal
radiotherapy using wedge compensation (3DCRT). The
decision about the fractionation regimen and radiation
technique was based on patient preference. Main factors
considered for the choice of the fractionation regimen by
the patients were distance to the radiotherapy department,
personal commitments limiting the overall treatment time
and recommendation of the treating physicians. Patients
not or not fully covered by medical insurance tended to
opt for 3DCRT for financial reasons. A few patients
with unfavourable thoracic geometry and left-sided
breast cancer were treated with seven-field IMRT.
These patients were not considered in the analysis.
Fractionation regimen and assessment of the acute skin
reaction
The conventional fractionation regimen (CF) for the
postoperative radiotherapy of the breast consisted of 28
Table 1 Dermatitis radiation according to the Common
Terminology Criteria for Adverse Events v4.03 (CTCAE)
Grade Description
1 Faint erythema or dry desquamation
2 Moderate to brisk erythema; patchy moist desquamation, mostly
confined to skin folds and creases; moderate edema
3 Moist desquamation in areas other than skin folds and creases;
bleeding induced by minor trauma or abrasion
4 Life-threatening consequences; skin necrosis or ulceration of full
thickness dermis; spontaneous bleeding from involved site; skin
graft indicated
5 Death
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fractions (fraction dose 1.8 Gy; total dose 50.4 Gy) and
for the chest wall of 25 fractions (fraction dose 2.0 Gy;
total dose 50.0 Gy). The hypofractionated regimen (HF)
for the breast or chest wall consisted of 15 fractions
(fraction dose 2.67 Gy; total dose 40.05 Gy). Where indi-
cated, the supraclavicular lymph nodes were treated with
the same fractionation regimen used for the breast or
the chest wall. Patients were treated once per day and
five times per week. If radiation fractions were missed,
patients were treated on weekends in order not to ex-
ceed the prescribed overall treatment time. Where indi-
cated, an electron boost was applied with five or eight
additional fractions with a fraction dose of 2.0 Gy.
For the analysis of the radiation reaction of the skin,
the maximal “dermatitis radiation” grade according to
CTCAE v4.03 was used observed during the CF or HF
of the whole breast or chest wall (before a possible boost
to the PTV; for CF at the planned dose of 50.4 Gy or
50.0 Gy, for HF at the planned dose of 40.05 Gy). Like-
wise, the time to the dermatitis radiation grade 1 or
grade 2 was defined as the time in days from the first ra-
diation fraction to the corresponding dermatitis radi-
ation grade observed during the course of the CF of HF
of the whole breast or chest wall (before a possible boost
to the PTV).
Treatment planning
A non-contrast CT-simulation was performed in the su-
pine position on a carbon breast board with the ipsilat-
eral arm up and head turned to the contralateral side.
Radio-opaque wires were used to mark the clinical
boundaries. A CT scan was performed using 5 mm slice
thickness. The CT scanning reference point was defined
using the CT simulation software Coherence Dosimetrist
(Siemens Medical, Germany), and target volumes (PTV
and OARs) using the software Coherence Oncologist
(Siemens Medical, Germany). The 3DCRT and IMRT
plans were generated using the treatment planning sys-
tem XIO 4.4 (CMS, Inc. of St. Louis, Mo, USA). Two
Siemens Oncor Anvantgarde linear accelerators with a
160 MLC Multileaf Collimator were used for the treat-
ment. The leaf width was 0.5 cm at the isocenter. The
dose calculation was determined using the “Superpos-
ition” algorithm. Dose volume histograms (DVH) of the
PTV and OARs of the 3D-CRT and IMRT plans were
generated. The target volumes were defined and the
dose prescribed according to the International Commis-
sion on Radiation Units and Measurement (ICRU) Re-
ports 50 and 62 recommendations. Accordingly, the
target volume should be surrounded by the 95 % isodose
line of the prescribed dose. The planning target volume
(PTV) definition for the whole breast or chest wall was
done according to the recommendations of the breast
cancer atlas for radiation therapy planning consensus
definitions of the Radiation Therapy Oncology Group
(RTOG) (http://www.rtog.org/CoreLab/ContouringAtlases/
BreastCancerAtlas.aspx). The PTV of the breast included
the apparent computed tomography (CT) glandular breast
tissue and the PTV of the chest wall the pectoralis muscle,
chest wall muscles, and ribs. For the statistical analysis the
volume of the PTV (breast or chest wall) was obtained
from the dose volume histograms of the 3DCRT or TB-
IMRT plans.
Daily online verification and correction of the patient
positioning error prior to radiotherapy was performed in
all patients using orthogonal megavoltage electronic por-
tal images [19]. No respiratory gating techniques were
applied in this study.
3DCRT plans
The dose was prescribed to the ICRU reference point
which was usually the isocenter located in the PTV vol-
ume centroid. Two tangential semi-opposed beams (to
avoid divergence), physical wedges (usually 15° or 30°), a
160 MLC Multileaf Collimator and 6 MV photons were
used for 3DCRT. A few patients received a mixed beam
technique (6 MV and 15 MV photons). The beam an-
gles, wedge angles, and beam weighting (usually min-
imal) were chosen to optimize coverage of the PTV,
while minimizing exposure to the ipsilateral lung, heart
and contralateral breast. Gantry angles ranged from
42° to 55° for the medial fields and from 224° to 232°
for the lateral fields for patients treated on the right
side, and from 305° to 322° for the medial fields and
from 133° to 147° for the lateral fields for patients
treated on the left side.
TB-IMRT plans
The same PTV and tangential beam orientation of the
3DCRT plans were used for the TB-IMRT plans. An ex-
tension into the air anteriorly of the chest of 1.5 cm was
added to the PTV to ensure appropriate opening of the
160 MLC Multileaf Collimator. Inverse treatment plan-
ning and 6MV photons were used for all IMRT plans.
The dose was prescribed to the PTV, and as initial dose
volume constraints the IMRT prescription table pro-
vided by the XIO treatment planning system was used
(Table 2). The IMRT plans were optimized to cover the
PTV and spare the surrounding tissues as much as pos-
sible. A step-and-shoot technique was applied. An
optimization with 100 iterations was then applied, and
followed by a semiautomatic segmentation (minimum
3 cm step size). Segments equal or less than 2 MU were
expelled from the plan. Tissue inhomogeneities were
considered in the treatment planning optimization
process, and the dose calculation algorithm used was
“Superposition”. The plans were developed to deliver
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95 % of the prescribed dose to the full PTV, and to
minimize dose to the OARs lung and heart.
Statistical analysis
Differences between patient groups treated with CF or HF
were assessed using the Chi-square test for categorical
variables, the t-test for normally distributed and the U-test
for non-normally distributed continuous variables. All
Table 2 Patient characteristics stratified by fractionation
regimen
Characteristic Total Fractionation regimen p value
CF HF
n % n % n %
Country of origin
Middle East 154 57.9 89 61.4 65 53.7 0.62
Africa 60 22.6 31 21.4 29 24.0
Asia 41 15.4 20 13.8 21 17.4
Europe/U.S.A. 11 4.1 5 3.4 6 5.0
Age at diagnosis (years)
Mean 49 49 49 0.85
Standard Deviation 10 9 10
≤40 53 19.9 29 20.0 24 19.8 0.99
41–50 103 38.7 55 37.9 48 39.7
51–60 84 31.6 47 32.4 37 30.6
>60 26 9.8 14 9.7 12 9.9
Laterality
Left breast 63 48.5 35 50.7 28 45.9 0.58
Right breast 67 51.5 34 49.3 33 54.1
Left chest wall 76 55.9 42 55.3 34 56.7 0.87
Right chest wall 60 44.1 34 44.7 26 43.3
Breast volume (ml)
Median 1132 1000 1235 0.01
Minimum 285 432 285
Maximum 3613 2929 3613
Chest wall volume (ml)
Median 715 695 776 0.02
Minimum 110 110 230
Maximum 2521 2521 1715
BMI
Median 30.6 29.9 31.4 0.16
Minimum 15.4 15.4 15.7
Maximum 67.3 66.4 67.3
<25 44 16.6 19 15.8 25 17.2 0.06
25.0–29.9 73 27.5 25 20.8 48 33.1
30.0–34.9 80 30.2 46 38.3 34 23.4
35.0–39.9 46 17.4 19 15.8 27 18.6
≥40.0 22 8.3 11 9.2 11 7.6
Menopausal status
Pre-menopausal 134 50.4 68 46.9 66 54.5 0.21
Post-menopausal 132 49.6 77 53.1 55 45.5
Histopathology
Invasive ductal cancer 246 92.5 135 93.1 111 91.7 0.05
Invasive lobular cancer 13 4.9 8 5.5 5 4.1
Table 2 Patient characteristics stratified by fractionation
regimen (Continued)
DCIS 5 1.9 0 0 5 4.1
Other 2 0.8 2 1.4 0 0
T classification
pTis 6 2.3 0 0.0 6 5.0 0.11
pT0 7 2.6 2 1.4 5 4.1
pT1 91 34.2 50 34.5 41 33.9
pT2 104 39.1 59 40.7 45 37.2
pT3 29 10.9 16 11.0 13 10.7
pT4 19 7.1 11 7.6 8 6.6
Not reported 10 3.8 7 4.8 3 2.5
N classification
pN0 96 36.1 48 33.1 48 39.7 0.19
pN1 76 28.6 42 29.0 34 28.1
pN2 56 21.1 28 19.3 28 23.1
pN3 31 11.7 21 14.5 10 8.3
Not reported 7 2.6 6 4.1 1 0.8
M classification
M0 263 98.9 143 98.6 120 99.2 0.67
M1 3 1.1 2 1.4 1 0.8
Grading
G1 22 8.3 5 3.4 17 14.0 0.02
G2 82 30.8 45 31.0 37 30.6
G3 137 51.5 80 55.2 57 47.1
Not reported 22 8.3 5 3.4 17 14.0
ER status
Negative 65 24.4 36 24.8 29 24.0 0.28
Positive 191 71.8 106 73.1 85 70.2
Not reported 10 3.8 3 2.1 7 5.8
PR status
Negative 15 5.6 7 4.8 8 6.6 0.76
Positive 79 29.7 42 29.0 37 30.6
Not reported 172 64.7 96 66.2 76 62.8
Her2/neu status
Negative 18 6.8 7 4.8 11 9.1 0.39
Positive 178 66.9 99 68.3 79 65.3
Not reported 70 26.3 39 26.9 31 25.6
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tests were two-sided, and a p-value of ≤0.05 was consid-
ered significant. To assess the impact of possible prognos-
tic factors on the maximal dermatitis radiation grade an
ordinal logistic regression analysis was performed. The
model selection of the multivariate analysis was performed
by a backward stepwise strategy. The possible prognostic
factors included in the analysis are listed in Table 4.
Results
The patient (Table 2) and treatment characteristics
(Table 3) were for the most part well balanced between
the patients treated with CF and HF. The volumes of the
PTV as well as the body mass index (BMI) were slightly
higher in the HF group. Furthermore, 97 % of the pa-
tients of the HF group completed their radiotherapy
within the prescribed overall treatment time compared
to 71 % of the CF group.
On univariate analysis, the fractionation regimen
(Fig. 1), the PTV (breast versus chest wall), the volume
of the PTV, and the BMI were significantly associated
with the maximal acute skin reaction. On multivariate
analysis, only the factors volume of the PTV (p = 0.0002)
and fractionation regimen (p < 0.00001) had a significant
independent impact on the maximal acute skin reaction
(Table 4). Furthermore, patients treated with HF devel-
oped the same acute skin reaction grade significantly
earlier compared to patients treated with CF (Table 3,
Fig. 2).
Discussion
Our data clearly show that a moderately hypofractio-
nated fractionation regimen (15 daily fractions of
2.67 Gy) results in a significantly less acute skin reaction
rate compared to CF in breast cancer radiotherapy.
Two recent randomized [20] and non-randomized
studies [21] comparing HF with CF have reported simi-
lar results. The randomized study allocated breast cancer
patients stage Tis-T2, N0-N1a, M0 (n = 287) to adjuvant
radiotherapy of the whole breast with either HF (16 daily
fractions of 2.67 Gy) or CF (25 daily fractions of 2.0 Gy.
Both study arms were followed by a tumor bed boost.
Patients were treated with megavoltage tangential portals
and forward- or inverse-planned segmental fields in su-
pine or prone position. Acute skin reactions were signifi-
cantly lower with HF compared to CF (CTCAE v4.0
dermatitis grade 2: 36 % versus 69 %; Ptrend < 0.001) [20].
The retrospective study compared the acute toxic effects
of 2309 patients receiving HF (daily fraction dose >2 Gy
(95 % were between 2.6 Gy and 2.7 Gy); mean total dose
(SD) 45.3 Gy (2.5 Gy); n = 578) versus CF (daily fraction
dose ≤2 Gy (62.9 % were 1.8 Gy and 37.1 % were
2.0 Gy); mean total dose (SD) 52.1Gy (2.8 Gy); n = 1732)
to the whole breast after breast conserving surgery. Sixty
percent of the patients treated with HF and 92.9 % of
Table 3 Treatment characteristics stratified by fractionation
regimen
Total Fractionation regimen p value
CF HF
n % n % n %
Fractionation regimen
266 100.0 145 100.0 121 100.0
Planning Target Volume (PTV)
Whole breast 130 48.9 69 47.6 61 50.4 0.65
Chest wall 136 51.1 76 52.4 60 49.6
Locoregional lymph nodes treated as part of plan
Yes 133 50.0 77 53.1 56 46.3 0.27
No 133 50.0 68 46.9 65 53.7
Boost to the PTV
Yes 129 48.5 83 57.2 46 38.0 <0.01
No 137 51.5 62 42.8 75 62.0
Radiation technique
3DCRT 115 43.2 73 50.3 42 34.7 0.01
TB-IMRT 151 56.8 72 49.7 79 65.3
Prolongation of the prescribed overall treatment time (days)
0 220 82.7 103 71.0 117 96.7 <0.001
1 20 7.5 18 12.4 2 1.7
2 13 4.9 12 8.3 1 0.8
3 6 2.3 5 3.4 1 0.8
4 5 1.9 5 3.4 0 0
5 2 08 2 1.4 0 0
Chemotherapy
Neo-adjuvant 198 74.4 115 79.3 83 68.6 0.10
Adjuvant 56 21.1 26 17.9 30 24.8
No chemotherapy 12 4.5 4 2.8 8 6.6
Hormone therapy
Yes 198 74.7 111 76.6 87 72.5 0.45
No 67 25.3 34 23.4 33 27.5
Maximal radiation dermatitis grade (CTC v4.0)a
0 20 7.5 7 4.8 13 10.7 <0.001
1 216 81.2 110 75.9 106 87.6
2 30 11.3 28 19.3 2 1.7
Time to dermatitis radiation grade 1 (days)a
Mean 17 21 13 <0.0001
Standard deviation 7 7 3
Time to dermatitis radiation grade 2 (days)a
Mean 34 35 21 <0.0001
Standard deviation 5 4 1
Abbreviation: a = Skin reactions observed during the radiotherapy of the whole
breast or chest wall (before the possible application of a boost to the PTV; for
CF at the planned dose of 50.4 Gy or 50.0 Gy, for HF at the planned dose
of 40.05 Gy)
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the patients treated with CF received a tumor bed boost.
The radiation techniques used were not described in de-
tail in this report. Acute skin reactions were significantly
lower with HF compared to CF (CTCAE v4.0 dermatitis
grade 2: 28 % versus 61 %; P < 0.001) [21]. Our study
showed a reduction of the CTCAE 4.0 dermatitis
radiation grade 2 from 19 % with CF to 2 % with HF.
The lower incidence of grade 2 dermatitis observed in
our study compared to the two above studies may be re-
lated to differences in the distribution of multiple prog-
nostic factors, for example the total dose. In the above
two studies the acute skin reactions were assessed




























Fig. 1 Maximal acute skin reaction stratified by fractionation regimen








Country of origin Middle East vs. Asia vs. Africa vs. Europe or U.S.A. 0.17
Age at diagnosis (years) ≤median vs. >median 0.61
Volume of the PTV (cm3) ≤median vs. >median 0.01 0.0002 1.52 0.72 2.32
BMI <25 vs. 25.0–29.9 vs. 30.0–34.9 vs. 35.0–39.9 vs. ≥40.0 0.03
Menopausal status Pre- vs. post-menopausal 0.56
T classification Tis, T0,T1,T2 vs. T3,T4 0.51
N classification N0 vs. N1, N2, N3 0.28
Grading G1, G2 vs. G3 0.61
ER status Negative vs. positive 0.98
PR status Negative vs. positive 0.79
Her2/neu status Negative vs. positive 0.38
Fractionation regimen CF vs. HF <0.0001 <0.00001 2.14 1.32 3.33
Planning Target Volume (PTV) Breast vs. chest wall 0.02
Locoregional lymph nodes treated as part
of plan
Yes vs. no 0.76
Radiation technique 3DCRT vs. TB-IMRT 0.42
Chemotherapy Neoadjuvant vs. adjuvant vs. no chemotherapy 0.22
Hormonal therapy Yes vs. no 0.60
Abbreviations: 95 % CI = 95 % confidence interval
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during the radiotherapy of the whole breast and the
tumor bed boost whereas in our study only during the
radiotherapy to the whole breast or chest wall (before
the possible application of a boost). Interestingly, the re-
ported incidence of CTCAE v.2–4 dermatitis radiation
grade 2 varies considerably between the studies with CF
(9 % [22], 14 % [23], 19 % [this study], 34 % [24], 37 %
[12], 61 % [21], 68 % [20] and 68 % [25], 72 % [14]), sug-
gesting that prognostic factors other than the daily frac-
tion dose and total dose significantly influence the acute
skin reaction. In our study, the fractionation regimen
and the volume of the PTV were identified as the only
significant independent prognostic factors for the max-
imal acute skin reaction grade. The breast volume as
prognostic factor for the acute skin reaction has been re-
ported by multiple studies [12, 14, 16, 22, 26–31]. This
observation has been explained with the association of
large breasts with increased dose inhomogeneity and hot
spots [31].
Several studies have reported an impact of the radi-
ation technique on the acute skin reaction [12–16].
IMRT can produce more homogenous dose distributions
compared to conventional tangential beam breast cancer
radiotherapy using wedge compensation, in particular if
compared to two-dimensionally planned breast cancer
radiotherapy [12, 32]. However, no significant difference
of the superficial dose in breast cancer radiotherapy has
been found between tangential beam IMRT (TB-IMRT)
and three-dimensional conformal radiotherapy using
tangential beams with wedge compensation (3DCRT) in
a phantom study [18] and a clinical study using
GafChromic film in vivo dosimetry [33]. The superficial
dose can be considered as a good surrogate parameter of
the skin dose. In agreement with the two in vitro and in
vivo dosimetry studies, no significant difference of the
acute skin reaction using TB-IMRT compared to 3DCRT
was found in our study on univariate and multivariate
analysis. An interesting observation in our study is that
patients treated with HF developed the same dermatitis
radiation grade significantly earlier than the patients
treated with CF. The data suggest that the daily fraction
size has a significant impact on the time to develop the
acute skin reaction, whereas the total dose is more rele-
vant for the severity of the acute skin reaction.
The strength of our study is the uniform prospective
assessment of the skin reaction and application of the
TB-IMRT and 3DCRT plans by the same team. Limita-
tions of our study are related to the non-randomized
study design where a selection bias cannot be excluded
with certainty. Furthermore, to obtain the maximal acute
skin reaction grade at comparable total doses, the skin
reaction during the radiotherapy of the whole breast or
chest wall (before the possible application of a boost)
was used in the analysis of our study. Some patients may
develop their maximal skin reaction after the completion
of the radiotherapy of the whole breast or chest wall,
and in these patients the maximal skin reaction would
have been underestimated. Some possible prognostic fac-
tors for the acute skin reaction have not been included
in our multivariate analysis, for example genetic markers
or smoking during radiotherapy [22, 26, 34].
Conclusion
Large randomized trials have established that hypofrac-
tionated regimens can be equally effective in terms of










































Fig. 2 Time to grade 1 and grade 2 acute skin reaction stratified by fractionation regimen
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compared to conventional fractionation schedules. Our
study shows that a moderately hypofractionated regimen
is also significantly associated with a reduced maximal
acute skin reaction.
Abbreviations
3DCRT, three-dimensional conformal radiotherapy; BMI, Body mass index; CF,
conventional fractionation; CT, computed tomography; CTCAE v4.03, common
terminology criteria for adverse events version 4.03; HF, hypofractionationation;
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